7 news items
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
LEGN
3 Jun 24
the potential benefit of CARVYTKI in this patient population
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
LEGN
23 May 24
the broad range of patients who will benefit from this one-time treatment," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
LEGN
13 May 24
to Legend Biotech manufacturing expectations for CARVYKTI®; and the potential benefits of Legend Biotech's product candidates. The words
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
LEGN
22 Apr 24
Biotech manufacturing expectations for CARVYKTI®; and the potential benefits of Legend Biotech's
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
JNJ
LEGN
NVS
8 Apr 24
Advisory Committee unanimously votes 11 to 0, supporting the favorable risk-benefit assessment of Carvykti based on results from
gwgyz
LEGN
8 Apr 24
lines of treatment."The results of the CARTITUDE-4 study demonstrated the substantial clinical benefit of cilta-cel infusion over standard
1qo pb1bj8v
LEGN
5 Apr 24
study demonstrated the substantial clinical benefit of cilta-cel infusion over standard of care continuous therapy in patients who experience a relapse
- Prev
- 1
- Next